Nivalon Medical

Nivalon Medical is a clinical-stage Danish biotechnology company focused on developing novel treatments for liver fibrosis and metabolic dysfunction-associated steatohepatitis (MASH). The company employs a de-risked drug development strategy by repurposing established small molecule compounds with known safety profiles for new therapeutic applications in hepatology. Its lead candidate, NVL-001, is designed to inhibit the progression of fibrosis and potentially reverse existing liver damage. Founded in 2021 and supported by the BioInnovation Institute, Nivalon aims to address significant unmet needs in chronic liver disease through accelerated clinical pathways.